

Joe Lombardo  
Governor  
  
Richard Whitley, MS  
Director



**DEPARTMENT OF  
HEALTH AND HUMAN SERVICES**  
DIVISION OF HEALTH CARE FINANCING AND POLICY  
*Helping people. It's who we are and what we do.*



Stacie Weeks,  
JD MPH  
Administrator

**Drug Utilization Review**

**Board Meeting Minutes**

**Date of Meeting:** Thursday, July 27, 2023

**Name of Organization:** The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP),  
Drug Use Review Board

Agenda Item	Record	Notes																											
<b>1. Call to Order and Roll Call</b>	<p>It was announced the meeting is being recorded.</p> <p>Chairperson Wheeler called the meeting to order at 1:04 p.m. on July 27, 2023.</p> <p>Chairperson Wheeler took the roll.</p> <table><thead><tr><th></th><th>Present</th><th>Absent</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Present	Absent	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<p><b>DHCFP Staff Present were as follows:</b></p> <ul style="list-style-type: none"><li>• Clemons, Roshanda, MD, Medical Director</li><li>• Griffin, Karen, Senior Deputy Attorney General (SDAG)</li><li>• Olsen, David, Chief of Pharmacy Services</li><li>• Gudino, Antonio, Manager of Pharmacy Services</li><li>• Flowers, Ellen, Program Officer I, Pharmacy Unit</li></ul> <p><b>Magellan Rx Staff Present were as follows:</b></p> <ul style="list-style-type: none"><li>• Mishra, Raj, Pharm.D., Clinical Account Manager</li><li>• Kim, James, Pharm.D., Dir. Clinical Account Services</li><li>• Martinez, Chris, Sr. Business Analyst</li></ul>
	Present	Absent																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>																											
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											

		<ul style="list-style-type: none"><li>• Killpack, Andy, Pharm.D., Dir. Specialty Clinical Solutions</li></ul> <p><b>Managed Care Organization representatives present were as follows:</b></p> <ul style="list-style-type: none"><li>• Lim, Luke, Pharm.D., Anthem</li><li>• Bitton, Ryan, Pharm.D., Health Plan of Nevada</li><li>• Beranek, Thomas, Pharm.D., Silver Summit Health Plan</li><li>• Tran, Jimmy, Pharm.D., Molina Healthcare</li></ul> <p><b>The public attendee list is included as Attachment A.</b></p> <p><b>Note:</b> Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list’s accuracy is not assured.</p>												
<b>2. General Public Comment</b>	Telephonic and web comment was called for, and the phone lines were opened.  No public comment was provided.													
<b>3. Administrative</b>														
<b>a. For Possible Action:</b> Review and Approve Meeting Minutes from April 20, 2023.	<p>Vice Chair Adeolokun moved to approve the minutes as presented, and Board Member England seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											

	<ul style="list-style-type: none"> <li>• Crystal Castaneda, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Jessica Cate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Brain Le, DO <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Rebecca Sparks, PA-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/></li> <li>• Jim Tran, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/></li> </ul>	
<b>b. Status Update by DHCFP</b>	<p>Chief of Pharmacy Services David Olsen provided five announcements.</p> <ul style="list-style-type: none"> <li>• On August 28th, we are holding a public hearing for a State Plan Amendment regarding the pricing and reimbursement for Physician Administered Drugs.</li> <li>• Providers should begin contacting Magellan to obtain prior authorization for specific drugs for the Fee-for-Service recipients for Physician Administered Drugs. Providers will be able to complete the prior authorization process through either web or phone. Also, in addition to the prior authorization program, there is now a fee schedule for Physician Administered Drugs. Please check the rates page on the DFCHP website for more information.</li> <li>• Due to the close of the 82nd legislative session, the Pharmacy Services Unit is working to implement a number of bills which will involve making updates to pharmacy policy. We are working on that now and those changes will be going forward over then the next seven to eight months.</li> <li>• We do have some organizational changes to announce, Dr Rashonda Clemens, who we have previously announced as the Nevada Medicaid Medical director will now be overseeing the Pharmacy Units as well as are Durable Medical Equipment Unit and will be combining into one unit.</li> <li>• Also, as a result of the 82nd Legislative Session, the Nevada Medicaid approved budget included the position of a Pharmacy Director. The position is posted at our HR website which is <a href="http://hr.nv.gov">hr.nv.gov</a> and if there is interest or you know someone that is</li> </ul>	

	<p>interested, CVs and resumes are welcome to be sent to our RX info@dhcfp.nv.gov inbox.</p> <ul style="list-style-type: none"> <li>• Our last announcement is that we would like to thank Antonio Brown, who has served as a state employee for approximately the past 10 years. Most of that with Nevada Medicaid. He is moving to a new position, it is still in pharmacy, but is no longer with the state. His last day will be August 4th and he is greatly appreciated and will be extremely missed.</li> </ul>	
<b>4. Clinical Presentations</b>		
<b>a. For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>Strensiq</b> .		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
ii. Presentation of utilization and clinical information.	<p>Dr. Raj Mishra provided the clinical background and indications for Strensiq.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Strensiq.</p> <ul style="list-style-type: none"> <li>• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li> </ul>	

iii.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members.  No comments were made.																																					
iv.	Proposed adoption of updated prior authorization criteria.	<p>Board Member Le moved to approve the criteria as presented by Magellan, and Board Member England seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table> <thead> <tr> <th></th><th>Yes</th><th>No</th><th>Abst.</th></tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
b.	For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>Myfembree</b> .																																						
i.	<u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Doctor Cassandra Lickert, Director of Medical Management Markets and Rowe with Sumitomo Pharma America, formerly known as Mylan Sciences.</p>																																					

ii.	Presentation of utilization and clinical information.	<p>Dr. Mishra provided the clinical background and indications for Myfembree.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Myfembree.</p> <ul style="list-style-type: none"><li>• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</li><li>• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</li><li>• Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li><li>• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li></ul>																																					
iii.	Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>																																					
iv.	Proposed adoption of updated prior authorization criteria.	<p>Chair Wheeler moved to approve the criteria as presented by Magellan, and Vice Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				

<p>c. <b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>Tzield</b>.</p>		
<p>i. <u>Public comment</u> on proposed clinical prior authorization criteria.</p>	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
<p>ii. Presentation of utilization and clinical information.</p>	<p>Dr. Mishra provided the clinical background and indications for Tzield.</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Tzield.</p> <ul style="list-style-type: none"> <li>• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li> </ul>	
<p>iii. Discussion by Board and review of utilization data.</p>	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>	
<p>iv. Proposed adoption of updated prior authorization criteria.</p>	<p>Vice Chair Adeolokun moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>	

	<div><div><div><div><div></div><div>Yes</div></div><div><div><div></div><div>No</div></div><div><div><div></div><div>Abst.</div></div></div></div><div><div><div><div>Jennifer Wheeler, Pharm.D., Chair</div><div>Netochi Adeolokun, Pharm.D., Vice Chair</div><div>Crystal Castaneda, MD</div><div>Jessica Cate, Pharm.D.</div><div>Dave England, Pharm.D.</div><div>Brain Le, DO</div><div>Rebecca Sparks, PA-C</div><div>Jim Tran, Pharm.D.</div></div><div><div><div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div><div><div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div><div><div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div><div><div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div><div><div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div><div><div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input checked="" type="checkbox"/></div></div><div><div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input checked="" type="checkbox"/></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div>	
<div><div><div>d. For Possible Action:</div><div>Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>infliximab biosimilars</b>.</div></div></div>		
<div><div><div>i. Public comment on proposed clinical prior authorization criteria.</div></div></div>	<div><div>Telephonic and web comment was called for, and the phone lines were opened.</div><div>Public comment was provided by Amy Hale pharmacist with Janssen scientific affairs.</div></div>	
<div><div><div>ii. Presentation of utilization and clinical information.</div></div></div>	<div><div>Dr. Mishra discussed the indications for infliximab biosimilars.</div><div>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of infliximab biosimilars.</div><div><div><div><div><div></div><div></div></div><div><div><div></div><div></div></div><div><div><div></div><div></div></div><div><div><div></div><div></div></div><div><div><div></div><div></div></div></div></div><div><div><div>Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</div><div>Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</div><div>Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</div><div>Dr. Tran with Molina Healthcare, approved of the proposed</div></div></div></div></div></div></div></div></div>	



	criteria and utilization presented.																																					
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members.  No comments were made.																																					
iv. Proposed adoption of updated prior authorization criteria.	Board Member Castaneda moved to approve the criteria as presented by Magellan, and Board Member Le seconded the motion.  A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):  <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
e. <b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>Opdivo</b> .																																						
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened.  Public comment was provided by Alexandra Sharer, Pharmacist with Field Health Economics and Outcomes Research Scientist at Bristol Myers Squibb.																																					

ii.	Presentation of utilization and clinical information.	<p>Dr. Andy Killpack discussed the indications for Opdivo.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Opdivo.</p> <ul style="list-style-type: none"><li>• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</li><li>• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</li><li>• Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li><li>• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li></ul>																																					
iii.	Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>																																					
iv.	Proposed adoption of updated prior authorization criteria.	<p>Vice Chair Adeolokun moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				

f. <b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>pemetrexed</b> .		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened.  No public comment was provided.	
ii. Presentation of utilization and clinical information.	Dr. Killpack discussed the indications for Pemetrexed.  Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization for Pemetrexed.  <ul style="list-style-type: none"> <li>• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li> </ul>	
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members.  No comments were made.	
iv. Proposed adoption of updated prior authorization criteria.	Board Member Le moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion.  A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):  <div style="text-align: right; margin-right: 100px;"> Yes    No    Abst.  <input checked="" type="checkbox"/>    <input type="checkbox"/>    <input type="checkbox"/> </div> <ul style="list-style-type: none"> <li>• Jennifer Wheeler, Pharm.D., Chair</li> </ul>	

	<ul style="list-style-type: none"> <li>• Netochi Adeolokun, Pharm.D., Vice Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Crystal Castaneda, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Jessica Cate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Brain Le, DO <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Rebecca Sparks, PA-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/></li> <li>• Jim Tran, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/></li> </ul>	
g. <b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>Perjeta</b> .		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>	
ii. Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for Perjeta.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Perjeta.</p> <ul style="list-style-type: none"> <li>• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li> </ul>	

iii.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members.  No comments were made.																																					
iv.	Proposed adoption of updated prior authorization criteria.	<p>Board Member Castaneda moved to approve the criteria as presented by Magellan, and Vice Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table> <tr> <th></th><th>Yes</th><th>No</th><th>Abst.</th></tr> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
h.	<b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>ranibizumab</b> .																																						
i.	<u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>																																					

ii.	Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for ranibizumab.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of ranibizumab.</p> <ul style="list-style-type: none"><li>• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</li><li>• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</li><li>• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li><li>• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li></ul>																																					
iii.	Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>																																					
iv.	Proposed adoption of updated prior authorization criteria.	<p>Board Member England moved to approve the criteria as presented by Magellan, and Vice Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
i.	<b>For Possible Action:</b> Discussion and possible																																						

	adoption of prior authorization criteria and/or quantity limits for <b>rituximab IV</b> .										
i.	<u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened.  No Public comment was provided.									
ii.	Presentation of utilization and clinical information.	Dr. Killpack discussed the indications for rituximab IV.  Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of rituximab IV.  <ul style="list-style-type: none"><li>• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</li><li>• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</li><li>• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li><li>• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li></ul>									
iii.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members.  <ul style="list-style-type: none"><li>• No comments were made.</li></ul>									
iv.	Proposed adoption of updated prior authorization criteria.	Vice Chair Adeolokun moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion.  A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):  <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.								
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>								

	<ul style="list-style-type: none"> <li>• Netochi Adeolokun, Pharm.D., Vice Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Crystal Castaneda, MD <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Jessica Cate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Brain Le, DO <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Rebecca Sparks, PA-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/></li> <li>• Jim Tran, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/></li> </ul>	
j. <b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>rituximab SQ</b> .		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>	
ii. Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for rituximab SQ.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of rituximab SQ.</p> <ul style="list-style-type: none"> <li>• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li> </ul>	



iii.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members.  No comments were made.																																					
iv.	Proposed adoption of updated prior authorization criteria.	<p>Board Member England moved to approve the criteria as presented by Magellan, and Board Member Le seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table> <tr> <th></th><th>Yes</th><th>No</th><th>Abst.</th></tr> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
k.	<b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>SCIG (immune globulin SQ)</b> .																																						
i.	<u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>																																					
ii.	Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for SCIG (immune globulin SQ).</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of SCIG (immune globulin SQ).</p>																																					

	<ul style="list-style-type: none"><li>• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</li><li>• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</li><li>• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li><li>• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li></ul>																																					
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members.  No comments were made.																																					
iv. Proposed adoption of updated prior authorization criteria.	<p>Vice Chair Adeolokun moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
I. <b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or																																						

quantity limits for <b>Soliris (eculizumab)</b> .																						
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened.  No Public comment was provided.																					
ii. Presentation of utilization and clinical information.	Dr. Killpack discussed the indications for Soliris (eculizumab).  Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Soliris (eculizumab).  <ul style="list-style-type: none"><li>• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</li><li>• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</li><li>• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li><li>• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li></ul>																					
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members.  No comments were made.																					
iv. Proposed adoption of updated prior authorization criteria.	Board Member Le moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion.  A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):  <table><tr><td></td><td>Yes</td><td>No</td><td>Abst.</td></tr><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																			
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																			
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																			
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																			
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																			

	<ul style="list-style-type: none"> <li>• Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Brain Le, DO <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/></li> <li>• Rebecca Sparks, PA-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/></li> <li>• Jim Tran, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/></li> </ul>	
m. <b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>Susvimo</b> .		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>	
ii. Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for Susvimo.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Susvimo.</p> <ul style="list-style-type: none"> <li>• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li> </ul>	
iii. Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>	

iv.	Proposed adoption of updated prior authorization criteria.	<p>Board Member England moved to approve the criteria as presented by Magellan, and Vice Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
n.	<b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>Tecentriq</b> .																																						
i.	<u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>																																					
ii.	Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for Tecentriq.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Tecentriq.</p> <ul style="list-style-type: none"><li>• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</li></ul>																																					

	<ul style="list-style-type: none"><li>• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</li><li>• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li><li>• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li></ul>																																					
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members.  No comments were made.																																					
iv. Proposed adoption of updated prior authorization criteria.	<p>Board Member Le moved to approve the criteria as presented by Magellan, and Board Member Castaneda seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
o. <b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>trastuzumab IV</b> .																																						

i.	Public comment on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>																													
ii.	Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for trastuzumab IV.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of trastuzumab IV.</p> <ul style="list-style-type: none"> <li>• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li> </ul>																													
iii.	Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>																													
iv.	Proposed adoption of updated prior authorization criteria.	<p>Board Member England moved to approve the criteria as presented by Magellan, and Chair Wheeler seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table> <tr> <th></th><th>Yes</th><th>No</th><th>Abst.</th></tr> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																												
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																												

	<ul style="list-style-type: none"> <li>Rebecca Sparks, PA-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/></li> <li>Jim Tran, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/></li> </ul>	
p. <b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>trastuzumab SQ</b> .		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>	
ii. Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for trastuzumab SQ.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of trastuzumab SQ.</p> <ul style="list-style-type: none"> <li>Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</li> <li>Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</li> <li>Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li> <li>Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li> <li></li> </ul>	
iii. Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>	



iv.	Proposed adoption of updated prior authorization criteria.	<p>Board Member England moved to approve the criteria as presented by Magellan, and Vice Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																				
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																				
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																				
q.	<b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>Ultomiris</b> .																																						
i.	<u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Alexandra Sharer pharmacist with BMS (Bristol Myers Squibb).</p>																																					
ii.	Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for Ultomiris.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Ultomiris.</p>																																					

	<ul style="list-style-type: none"><li>• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</li><li>• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</li><li>• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li><li>• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li></ul>																																					
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members.  No comments were made.																																					
iv. Proposed adoption of updated prior authorization criteria.	<p>Board Member Castaneda moved to approve the criteria as presented by Magellan, and Vice Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Crystal Castaneda, MD	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
r. <b>For Possible Action:</b> Discussion and possible adoption of prior																																						

authorization criteria and/or quantity limits for <b>Yervoy</b> .		
I. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>	
II. Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for Yervoy.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Yervoy.</p> <ul style="list-style-type: none"> <li>• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li> </ul>	
III. Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>	
IV. Proposed adoption of updated prior authorization criteria.	<p>Board Member Castaneda moved to approve the criteria as presented by Magellan, and Vice Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>	

	<ul style="list-style-type: none"> <li>• Jennifer Wheeler, Pharm.D., Chair</li> <li>• Netochi Adeolokun, Pharm.D., Vice Chair</li> <li>• Crystal Castaneda, MD</li> <li>• Jessica Cate, Pharm.D.</li> <li>• Dave England, Pharm.D.</li> <li>• Brain Le, DO</li> <li>• Rebecca Sparks, PA-C</li> <li>• Jim Tran, Pharm.D.</li> </ul>	Yes <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	No <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	Abst. <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input checked="" type="checkbox"/>	
s. <b>For Possible Action:</b> Discussion and possible adoption of prior authorization criteria and/or quantity limits for <b>Zynlonta</b> .					
I. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No Public comment was provided.</p>				
II. Presentation of utilization and clinical information.	<p>Dr. Killpack discussed the indications for Zynlonta.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of Zynlonta.</p> <ul style="list-style-type: none"> <li>• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</li> <li>• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.</li> </ul>				

	<ul style="list-style-type: none"><li>Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</li></ul>																																					
III. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members.  No comments were made.																																					
IV. Proposed adoption of updated prior authorization criteria.	<p>Board Member Castaneda moved to approve the criteria as presented by Magellan, and Board Member England seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td><ul style="list-style-type: none"><li>Jennifer Wheeler, Pharm.D., Chair</li></ul></td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td><ul style="list-style-type: none"><li>Netochi Adeolokun, Pharm.D., Vice Chair</li></ul></td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td><ul style="list-style-type: none"><li>Crystal Castaneda, MD</li></ul></td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td><ul style="list-style-type: none"><li>Jessica Cate, Pharm.D.</li></ul></td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td><ul style="list-style-type: none"><li>Dave England, Pharm.D.</li></ul></td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td><ul style="list-style-type: none"><li>Brain Le, DO</li></ul></td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td><ul style="list-style-type: none"><li>Rebecca Sparks, PA-C</li></ul></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td><ul style="list-style-type: none"><li>Jim Tran, Pharm.D.</li></ul></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	<ul style="list-style-type: none"><li>Jennifer Wheeler, Pharm.D., Chair</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<ul style="list-style-type: none"><li>Netochi Adeolokun, Pharm.D., Vice Chair</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<ul style="list-style-type: none"><li>Crystal Castaneda, MD</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<ul style="list-style-type: none"><li>Jessica Cate, Pharm.D.</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<ul style="list-style-type: none"><li>Dave England, Pharm.D.</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<ul style="list-style-type: none"><li>Brain Le, DO</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<ul style="list-style-type: none"><li>Rebecca Sparks, PA-C</li></ul>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<ul style="list-style-type: none"><li>Jim Tran, Pharm.D.</li></ul>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																																			
<ul style="list-style-type: none"><li>Jennifer Wheeler, Pharm.D., Chair</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<ul style="list-style-type: none"><li>Netochi Adeolokun, Pharm.D., Vice Chair</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<ul style="list-style-type: none"><li>Crystal Castaneda, MD</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<ul style="list-style-type: none"><li>Jessica Cate, Pharm.D.</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<ul style="list-style-type: none"><li>Dave England, Pharm.D.</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<ul style="list-style-type: none"><li>Brain Le, DO</li></ul>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																			
<ul style="list-style-type: none"><li>Rebecca Sparks, PA-C</li></ul>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
<ul style="list-style-type: none"><li>Jim Tran, Pharm.D.</li></ul>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																			
<b>5. DUR Board Requested Reports</b>																																						
a. Opioid Reports: i. Opioid Trends ii. Count of Claims iii. Med Trend iv. Top Members v. Top Prescribers vi. Top Pharmacy	<ul style="list-style-type: none"><li>Dr. Mishra presented opioid utilization reports.</li><li>Dr. Lim presented opioid utilization reports.</li><li>Dr. Bitton presented opioid utilization reports.</li><li>Dr. Beranek presented opioid utilization reports.</li><li>Dr. Tran presented opioid utilization reports.</li></ul> <p>Chairperson Wheeler asked for comments from Board Members regarding Opioid Reports. The board discussed utilization and trends. No additional action taken or motions for investigative referrals.</p>																																					

b. Standard DUR Reports: <ul style="list-style-type: none"> <li>i. Top 10 Classes by Amount Paid</li> <li>ii. Top 10 Classes by Claim Count</li> <li>iii. Quarterly ProDUR Paid Claims Saving Report</li> <li>iv. Retro DUR Initiatives</li> </ul>	<ul style="list-style-type: none"> <li>• Dr. Mishra presented Standard DUR Reports</li> <li>• Dr. Lim presented Standard DUR Reports.</li> <li>• Dr. Bitton presented Standard DUR Reports</li> <li>• Dr. Beranek presented Standard DUR Reports</li> <li>• Dr. Tran presented Standard DUR Reports.</li> </ul>	
<b>6. Closing Discussion</b>		
a. Public Comment	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
b. For Possible Action: Date and location of the next meeting.	<p>Chairperson Wheeler stated the next meeting is scheduled for October 19, 2023.</p> <p>Location: Hilton Garden Inn Reno</p> <p>Meeting adjourned at 3:04 pm</p>	

#### Attachment A – Members of the Public in Attendance

Sharer, Alexandra  
Santarone, Christopher  
Martinez, Shannan /US  
Cassandra Lickert  
Rushi Parikh

Deb G (Guest)  
Hylla, Scott  
Hale, Amy [JANUS]  
Michele Puyear (Guest)  
Jared Godwin

D'Ambrosio, Beth  
McCutchan, Frank /US  
Levin, Amy, MD  
Michael Zarob  
GNH (Gina Heinen)

Borysyuk, Maribel /US  
Mark Rosenberg  
Sandee Merrick  
Chris Johnson  
Roa, Ryan A

Matthew Wright  
Karen Ou (Guest)  
McNair, LaTanya  
Jessica Cate (Guest)  
Cheryl Donahue

Michael Pazirandeh  
Sacro, Janssen  
Bobby White

**Attachment B – Submitted Written Comment**

None